Single cEll pRofiling PErsistaNce To ImmuNothErapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions

Colorectal CancerEndometrial Cancer

Interventions

DRUG

Durvalumab

Durvalumab 1500 mg IV every 4 weeks

DRUG

Tremelimumab

Tremelimumab 300 mg IV as a single dose

Trial Locations (1)

RECRUITING

Vall d'Hebron Institute of Oncology, Barcelona

All Listed Sponsors

lead

Vall d'Hebron Institute of Oncology

OTHER